HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.